The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prediction of therapy failure after VEGF-based first-line treatment of kidney cancer patients by DNA hypermethylation biomarkers.
Inga Peters
No relevant relationships to disclose
Natalia Dubrowskaja
No relevant relationships to disclose
Mahmoud Abbas
No relevant relationships to disclose
Christoph Seidel
No relevant relationships to disclose
Michael Kogosov
No relevant relationships to disclose
Ralph Scherer
No relevant relationships to disclose
Kai Gebauer
No relevant relationships to disclose
Axel S. Merseburger
No relevant relationships to disclose
Markus A. Kuczyk
No relevant relationships to disclose
Viktor Grünwald
No relevant relationships to disclose
Juergen Serth
No relevant relationships to disclose